Dr Berg reported speakers bureau fees from Eisai, Exelexis, and Bristol Meyers Squibb outside the submitted work. Dr Bashir reported research funding to institution from Amgen, Artios Pharmaceuticals Bicycle Therapeutics, Boehringer Ingelheim, Daiichi Snakyo, KAHR, Merck, Pionyr Immunotherapeutics, RASCAL Therapeutics, Syros Pharmaceuticals,and Tarveda Therapeutics. Dr Gulati reported support to institution for a clinical trial from AstraZenca and Isoray, and personal fees from EMD Serono for advisory board roles outside the submitted work. Dr Labaki reported grants from Genentech/imCORE outside the submitted work. This cohort study found that in patients with cancer and COVID-19, administration of systemic anticancer therapies, especially IO, in the context of baseline immunosuppression was associated with severe clinical outcomes and the development of cytokine storm.Ĭ Identifier: NCT04354701.Ĭonflict of Interest Disclosures: Dr Bakouny reported nonfinancial support from Bristol Myers Squibb, grants from Genentech/imCORE, and personal fees from UpToDate outside the submitted work. Patients with immunosuppression receiving non-IO therapies (vs untreated) also had worse COVID-19 severity (aOR, 1.79 95% CI, 1.36-2.35) and cytokine storm (aOR, 2.32 95% CI, 1.42-3.79). Although no difference in COVID-19 severity and cytokine storm was found in the IO group compared with the untreated group in the total cohort (adjusted odds ratio, 0.80 95% CI, 0.56-1.13, and aOR, 0.89 95% CI, 0.41-1.93, respectively), patients with baseline immunosuppression treated with IO (vs untreated) had worse COVID-19 severity and cytokine storm (aOR, 3.33 95% CI, 1.38-8.01, and aOR, 4.41 95% CI, 1.71-11.38, respectively). A total of 599 (5.0%) patients received IO, whereas 4327 (35.9%) received non-IO systemic anticancer therapies, and 7120 (59.1%) did not receive any antineoplastic regimen within 3 months prior to COVID-19 diagnosis. The median age of the entire cohort was 65 years (interquartile range, 54-74) years and 6359 patients were female (52.8%) and 6598 (54.8%) were non-Hispanic White. The secondary outcome was the occurrence of cytokine storm. The primary outcome was a 5-level ordinal scale of COVID-19 severity: no complications hospitalized without requiring oxygen hospitalized and required oxygen intensive care unit admission and/or mechanical ventilation death. Immunosuppression due to therapy systemic anticancer therapy (IO or non-IO). Records analyzed included patients with active or previous cancer who had a laboratory-confirmed infection with SARS-CoV-2 by polymerase chain reaction and/or serologic findings. The CCC19 registry is a centralized international multi-institutional registry of patients with COVID-19 with a current or past diagnosis of cancer. This registry-based retrospective cohort study included 12 046 patients reported to the COVID-19 and Cancer Consortium (CCC19) registry from March 2020 to May 2022. To determine the association of baseline immunosuppression and/or IO-based therapies with COVID-19 severity and cytokine storm in patients with cancer. Lionsgate is handling global sales.Cytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation. The film is currently shooting in Georgia. She is represented by CAA, Gilbertson Entertainment and Jackoway Austen Tyerman Wertheimer Mandelbaum Morris Bernstein Trattner & Klein.īartlett is repped by UTA, Heroes and Villains Entertainment, and attorneys Hirsch Wallerstein Hayum Matlof and Fishman. She recently wrapped production on the crime thriller Finest Kind directed by Oscar winner Brian Helgeland, was last seen starring in A24’s X and HBO’s The Fallout. In January she starred in the $140M-global grossing Scream and is set to reprise her role in the hit franchise’s sixth installment. Ortega will next star in the title role of the Tim Burton Netflix series Wednesday, centering on the Addams Family character. Erin Westerman, President of Production for the Lionsgate Motion Picture Group, tells Deadline, “While we are excited for the movie to speak for itself, the level of talent assembled for this special film is a testament to Jade, whose screenplay lures you in with her dazzling voice.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |